UFC featherweight Chad Mendes fought for the title vs. Jose Aldo, twice. He has been among the best in the world for five years or more. And now he is suspended for two years, until June 10, 2018.
The fighter failed a out-of-competition PED test administered on May 17 by USADA, the UFC’s independent drug-test agency. The prohibited drug was GHRP-6, a Growth Hormone Releasing Hexapeptide. The performance enhancing drug aids fat loss, increases, muscle gain, and reduces inflammation and helping to heal injury, particularly tendinitis.
The announcement came via USADA’s
website.
USADA announced today that UFC athlete Chad Mendes, of Sacramento, Calif., has received a two-year sanction for an anti-doping policy violation after testing positive for a prohibited substance.
Mendes, 31, tested positive for GHRP-6 (Growth Hormone-Releasing Hexapeptide) following an out-of-competition urine test conducted on May 17, 2016. GHRP-6 is a prohibited substance in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List.
Growth Hormone-Releasing Peptides are listed as Non-Specified Substances on the WADA Prohibited List. Under the UFC Anti-Doping Policy, the standard sanction for an anti-doping policy violation involving a Non-Specified Substance is a two-year period of ineligibility.
Mendes’ two-year period of ineligibility began on June 10, 2016, the date on which he received a provisional suspension. In addition, Mendes has been disqualified from all competitive results obtained on and subsequent to May 17, 2016, the date of sample collection, including forfeiture of any title, ranking, purse or other compensation.
